These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3659049)

  • 1. Management of hormone resistant stage C and D prostatic cancer.
    Khoury S
    Prog Clin Biol Res; 1987; 243B():513-20. PubMed ID: 3659049
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of hormone resistant stage C and D prostatic cancer.
    Khoury S
    Prog Clin Biol Res; 1989; 303():347-52. PubMed ID: 2674996
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of radiotherapy in the treatment of hormone-resistant stage C lesions.
    Bagshaw MA
    Prog Clin Biol Res; 1987; 243B():473-8. PubMed ID: 3659043
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary treatment of stage C and D prostatic cancer: conclusions.
    Jardin A
    Prog Clin Biol Res; 1987; 243B():455-6. PubMed ID: 3659040
    [No Abstract]   [Full Text] [Related]  

  • 5. Experimental and theoretical basis for hormonal treatment of prostatic cancer.
    Carter HB; Isaacs JT
    Semin Urol; 1988 Nov; 6(4):262-8. PubMed ID: 3068765
    [No Abstract]   [Full Text] [Related]  

  • 6. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
    Eisenberger MA; Crawford ED; Wolf M; Blumenstein B; McLeod DG; Benson R; Dorr FA; Benson M; Spaulding JT
    Semin Oncol; 1994 Oct; 21(5):613-9. PubMed ID: 7939752
    [No Abstract]   [Full Text] [Related]  

  • 8. Palliative pelvic radiotherapy in patients with hormone-resistant prostatic cancer.
    Fosså SD
    Prog Clin Biol Res; 1987; 243B():479-85. PubMed ID: 2443925
    [No Abstract]   [Full Text] [Related]  

  • 9. Staging of M0 prostatic adenocarcinoma: how aggressive should one be?
    Olsson CA
    Prog Clin Biol Res; 1984; 153():455-67. PubMed ID: 6473408
    [No Abstract]   [Full Text] [Related]  

  • 10. [Renaissance of estrogen therapy in advanced prostate carcinoma?].
    Smith PH; Robinson MR
    Urologe A; 1995 Sep; 34(5):393-7. PubMed ID: 7483156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modern approaches to treating locally-advanced and disseminated prostate cancer].
    Veliev EI
    Ter Arkh; 2002; 74(10):67-70. PubMed ID: 12469638
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostatic transitional cell carcinoma: pathologic features and clinical management.
    Shen SS; Lerner SP
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1155-62. PubMed ID: 18028024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of stage C prostate cancer.
    deKernion JB; Mukamel E
    Prog Clin Biol Res; 1987; 243B():403-9. PubMed ID: 3309992
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of hormone-resistant prostate cancer.
    Gibbons RP
    Prog Clin Biol Res; 1989; 303():337-45. PubMed ID: 2674995
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical and biological study of androgen independent prostate cancer (AI PCa).
    Logothetis CJ; Hoosein NM; Hsieh JT
    Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of endocrine therapy of prostate cancer by assessing tumor markers and hormone parameters. Hormonal "cross-over" treatment of false endocrine independent tumors.
    Kraljić I; Tarle M
    Prog Clin Biol Res; 1987; 243B():521-5. PubMed ID: 3659050
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relationship between HER-2/neu over-expression and androgen independent prostate cancer].
    Bai Q; Chen F; Qi J; Chen JH; Wang YX
    Zhonghua Nan Ke Xue; 2007 May; 13(5):414-6. PubMed ID: 17569256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 20. Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies.
    Friedlander JI; Duty BD; Okeke Z; Smith AD
    J Endourol; 2012 Feb; 26(2):102-9. PubMed ID: 22192109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.